Terms: = Breast cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Treatment
115 results:
1. The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
Wang J; Tian C; Zheng BJ; Zhang J; Jiao DC; Qu JR; Liu ZZ
BMC Cancer; 2024 May; 24(1):549. PubMed ID: 38693523
[TBL] [Abstract] [Full Text] [Related]
2. Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T; Iwamoto T; Niikura N; Watanabe K; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
ESMO Open; 2024 Apr; 9(4):102385. PubMed ID: 38387111
[TBL] [Abstract] [Full Text] [Related]
3. Concurrent Use of Statins in Patients Undergoing Curative Intent treatment for Triple Negative breast cancer: A Systematic Review and Meta-Analysis.
McKechnie T; Brown Z; Lovrics O; Yang S; Kazi T; Eskicioglu C; Parvez E
Clin Breast Cancer; 2024 Apr; 24(3):e103-e115. PubMed ID: 38296737
[TBL] [Abstract] [Full Text] [Related]
4. Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer.
Li C; Yang L; Zhang Y; Hou Q; Wang S; Lu S; Tao Y; Hu W; Zhao L
Front Immunol; 2023; 14():1307588. PubMed ID: 38235137
[TBL] [Abstract] [Full Text] [Related]
5. Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study.
Digkas E; Smith DR; Wennstig AK; Matikas A; Tegnelius E; Valachis A
Breast Cancer Res Treat; 2024 Feb; 204(1):79-87. PubMed ID: 38057688
[TBL] [Abstract] [Full Text] [Related]
6. Combination of runx1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract] [Full Text] [Related]
7. Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.
Charton E; Baldini C; Fayet Y; Schultz E; Auroy L; Vallier E; Italiano A; Robert M; Coquan E; Isambert N; Moreau P; Touzeau C; Le Tourneau C; Ghrieb Z; Kiladjian JJ; Delord JP; Gomez Roca C; Vey N; Barlesi F; Lesimple T; Penel N; Soria JC; Massard C; Besle S
ESMO Open; 2023 Aug; 8(4):101610. PubMed ID: 37536254
[TBL] [Abstract] [Full Text] [Related]
8. cancer survival analysis and spatial distribution during 2014-2016 in Shandong Province, China.
Jiang F; Fu Z; Lu Z; Chu J; Xu A; Guo X; Ma J
Sci Rep; 2023 Jun; 13(1):10324. PubMed ID: 37365230
[TBL] [Abstract] [Full Text] [Related]
9. Profiling the Somatic Mutational Landscape of breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
Ding YC; Song H; Adamson AW; Schmolze D; Hu D; Huntsman S; Steele L; Patrick CS; Tao S; Hernandez N; Adams CD; Fejerman L; Gardner K; Nápoles AM; Pérez-Stable EJ; Weitzel JN; Bengtsson H; Huang FW; Neuhausen SL; Ziv E
Cancer Res; 2023 Aug; 83(15):2600-2613. PubMed ID: 37145128
[TBL] [Abstract] [Full Text] [Related]
10. Assessment of the cardiorespiratory fitness and the quality of life of patients with breast cancer undergoing chemotherapy: a prospective study.
Akyol M; Tuğral A; Arıbaş Z; Bakar Y
Breast Cancer; 2023 Jul; 30(4):617-626. PubMed ID: 36952220
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea.
Yun J; Song H; Kim SM; Kim S; Kwon SR; Lee YE; Jeong D; Park JH; Kwon S; Yun H; Lee DS
Hum Genomics; 2023 Feb; 17(1):13. PubMed ID: 36814285
[TBL] [Abstract] [Full Text] [Related]
12. [Validity and reliability of DASH questionnaire in women who suffer from lymphedema as a side effect of a breast cancer treatment].
Puentes Gutiérrez AB; García Bascones M; Jiménez Díaz F; Cuena Boy R; Puentes Gutiérrez R
Rehabilitacion (Madr); 2023; 57(3):100780. PubMed ID: 36739630
[TBL] [Abstract] [Full Text] [Related]
13. Follow-up strategy and survival for five common cancers: A meta-analysis.
Galjart B; Höppener DJ; Aerts JGJV; Bangma CH; Verhoef C; Grünhagen DJ
Eur J Cancer; 2022 Oct; 174():185-199. PubMed ID: 36037595
[TBL] [Abstract] [Full Text] [Related]
14. Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer.
von Au A; Shencoru S; Uhlmann L; Mayer L; Michel L; Wallwiener M; Hennigs A; Deutsch T; Riedel F; Heil J; Golatta M; Schneeweiss A; Schütz F; Domschke C
Arch Gynecol Obstet; 2023 Apr; 307(4):1105-1113. PubMed ID: 35980458
[TBL] [Abstract] [Full Text] [Related]
15. Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With breast cancer: The MA.32 Randomized Clinical Trial.
Goodwin PJ; Chen BE; Gelmon KA; Whelan TJ; Ennis M; Lemieux J; Ligibel JA; Hershman DL; Mayer IA; Hobday TJ; Bliss JM; Rastogi P; Rabaglio-Poretti M; Mukherjee SD; Mackey JR; Abramson VG; Oja C; Wesolowski R; Thompson AM; Rea DW; Stos PM; Shepherd LE; Stambolic V; Parulekar WR
JAMA; 2022 May; 327(20):1963-1973. PubMed ID: 35608580
[TBL] [Abstract] [Full Text] [Related]
16. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
; Bradbury CA; Lawler PR; Stanworth SJ; McVerry BJ; McQuilten Z; Higgins AM; Mouncey PR; Al-Beidh F; Rowan KM; Berry LR; Lorenzi E; Zarychanski R; Arabi YM; Annane D; Beane A; van Bentum-Puijk W; Bhimani Z; Bihari S; Bonten MJM; Brunkhorst FM; Buzgau A; Buxton M; Carrier M; Cheng AC; Cove M; Detry MA; Estcourt LJ; Fitzgerald M; Girard TD; Goligher EC; Goossens H; Haniffa R; Hills T; Huang DT; Horvat CM; Hunt BJ; Ichihara N; Lamontagne F; Leavis HL; Linstrum KM; Litton E; Marshall JC; McAuley DF; McGlothlin A; McGuinness SP; Middeldorp S; Montgomery SK; Morpeth SC; Murthy S; Neal MD; Nichol AD; Parke RL; Parker JC; Reyes LF; Saito H; Santos MS; Saunders CT; Serpa-Neto A; Seymour CW; Shankar-Hari M; Singh V; Tolppa T; Turgeon AF; Turner AM; van de Veerdonk FL; Green C; Lewis RJ; Angus DC; McArthur CJ; Berry S; Derde LPG; Webb SA; Gordon AC
JAMA; 2022 Apr; 327(13):1247-1259. PubMed ID: 35315874
[TBL] [Abstract] [Full Text] [Related]
17. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
de Gregorio A; Janni W; Friedl TWP; Nitz U; Rack B; Schneeweiss A; Kates R; Fehm T; Kreipe H; Christgen M; Kümmel S; Trapp E; Wuerstlein R; Hartkopf A; Clemens M; Reimer T; Häberle L; Fasching PA; Gluz O; Harbeck N
Br J Cancer; 2022 Jun; 126(12):1715-1724. PubMed ID: 35194193
[TBL] [Abstract] [Full Text] [Related]
18. Modifying the Microbiome as a Potential Mechanism of Photobiomodulation: A Case Report.
Bicknell B; Laakso EL; Liebert A; Kiat H
Photobiomodul Photomed Laser Surg; 2022 Feb; 40(2):88-97. PubMed ID: 34962422
[No Abstract] [Full Text] [Related]
19. Ovarian stimulation for fertility treatments and risk of breast cancer: a matched cohort study.
Machtinger R; Fallach N; Goldstein I; Chodick G; Schiff E; Orvieto R; Mashiach R
Hum Reprod; 2022 Mar; 37(3):577-585. PubMed ID: 34871410
[TBL] [Abstract] [Full Text] [Related]
20. Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer.
Tejera D; Rana M; Basik M; Boileau JF; Margolese R; Prakash I; Meguerditchian AN; Muanza T; Monette J; Wong SM
Breast Cancer Res Treat; 2021 Dec; 190(3):491-501. PubMed ID: 34542772
[TBL] [Abstract] [Full Text] [Related]
[Next]
